Actuate Therapeutics Inc(ACTU) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 22 at 4:00 PM ET (Korea 10/23 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.89 | Insider Own | 57.42% | Shs Outstand | 24.0M | Perf Week | 3.26% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | 8.72% | Insider Trans | - | Shs Float | 10.2M | Perf Month | -29.44% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | -0.17 | Inst Own | 14.23% | Short Float | 13% | Perf Quarter | -56.25% |
| Income | -0.02B | P/S | - | EPS this Y | 31.45% | Inst Trans | -3.36% | Short Ratio | 3.8 | Perf Half Y | -79.6% |
| Sales | 0.00B | P/B | 12.53 | EPS next 5Y | 13.33% | ROA | -336.18% | Short Interest | 1.33M | Perf YTD | -91.57% |
| Book/sh | 0.04 | P/C | 2.8 | EPS past 3/5Y | -0.08% - | ROE | -553.75% | 52W High | -93.47% ($7.90) | Perf Year | -92.82% |
| Cash/sh | 0.18 | P/FCF | - | Sales past 3/5Y | - | ROIC | -1467.12% | 52W Low | 25.9% ($0.41) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 29.39% | Gross Margin | - | Volatility(W/M) | 27.07% 21.95% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.14 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.25 | EPS Q/Q | 32.66% | Profit Margin | - | RSI (14) | 37.17 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.25 | Sales Q/Q | - | SMA20 | -21.98% ($0.67) | Beta | 1.19 | Target Price | $10.25 |
| Payout | - | Debt/Eq | 0.4 | Earnings | 2026/09/02 | SMA50 | -47.18% ($0.98) | Rel Volume | 0.96 | Prev Close | $0.56 |
| Employees | 12 | LT Debt/Eq | 0.4 | EPS/Sales Surpr. | 1.62% - | SMA200 | -77.78% ($2.34) | Avg Volume(3M) | 0.35M | Price | $0.52 |
| IPO | 2024/8/13 | Option/Short | No/Yes | Trades | 675 | Volume | 335,045 | Change | -8.18% |
A clinical-stage biotech company developing innovative small-molecule oncology drugs that block specific enzymes that help cancer cells grow, in order to treat hard-to-treat cancers such as pancreatic cancer.
Over the past 1 year, on the lower side
93% below its 1-year high.
Traded about as much as usual. That is 96% of its average volume.
ACTU has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +31.4% this year.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 14.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #488 of 594 in the industry
Based on market cap of $12M.
PLUR#485 Pluri Inc $13M PER - 
HIND#486 Vyome Holdings Inc $13M PER - 
ICU#487 SeaStar Medical Holding Corp $13M PER - ACTU#488 Actuate Therapeutics Inc $12M PER - 
KPTI#489 Karyopharm Therapeutics Inc $12M PER - 
FAQ
What kind of company is ACTU?
ACTU belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ACTU?
The market cap of ACTU is approximately $12M, ranking 5,377 within its sector.
What is the 52-week high and low for ACTU?
ACTU has recorded a 52-week high of $7.90 and a low of $0.41.
